Nano-based drug delivery system

Eskiler, Gamze Güney; Dıkmen, Gökhan; Genc, Lufti

doi:10.5599/obp.8.3

Cited by 4 publications

(2 citation statements)

References 136 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pitfalls of conventional drug administration, such as nonspecific/systemic biodistribution, the long-term unsustainability of drug molecules due to high metabolic rate, and high global cytotoxicity, pose a challenge for the efficient treatment of chronic diseases [1]. Nanotherapeutics is an emerging field, addressing these limitations and drawbacks by utilizing nanoscale complexes consisting of nanocarriers and therapeutic drugs for target tissue/cell-specific treatment, as demonstrated in recent clinical studies [2][3][4][5].…”

Section: Introductionmentioning

confidence: 99%

Magneto- and opto-stimuli responsive nanofibers as a controlled drug delivery system

et al. 2021

View full text Add to dashboard Cite

The drawbacks of conventional drug administration include repeated administration, non-specific biodistribution in the body’s systems, the long-term unsustainability of drug molecules, and high global cytotoxicity, posing a challenge for the efficient treatment of chronic diseases that require varying drug dosages over time for optimal therapeutic efficacy. Most controlled-release methods encapsulate drug molecules in biodegradable materials that dissolve over time to release the drug, making it difficult to deliver drugs on a schedule. To address these limitations, we developed a magneto-, opto-stimuli responsive drug delivery system based on functionalized electrospun nanofibers loaded with superparamagnetic iron oxide nanoparticles (SPIONs). We exploited the Néel relaxation effect of SPIONs, where heat generated from vibrating SPIONs under exogenously applied magnetic fields or laser illumination induced structural changes of the thermo-sensitive nanofibers that encapsulate the particles. We showed that this structural change of nanofibers is the governing factor in controlling the release of dye molecules, used as a model drug and co-encapsulated within the nanofibers. We also showed that the degree of nanofiber structural change depends on SPION loading and duration of stimulation, demonstrating the tunability of the drug release profile. Overall, we demonstrated the potential of SPION-embedded thermoplastic nanofibers as an attractive platform for on-demand drug delivery.

show abstract

Section: Introductionmentioning

confidence: 99%

Magneto- and opto-stimuli responsive nanofibers as a controlled drug delivery system

et al. 2021

View full text Add to dashboard Cite

show abstract

“…SLNs consist of biodegradable physiological lipids stabilized by surfactant and spherical particles of ranging in size from 1 to 1,000 nm. Thus, SLNs offer successful incorporation of active compounds and controlled drug release at specific site (Cavaco et al, 2017; Guney Eskiler, Cecener, Egeli, & Tunca, 2018b; Guney Eskiler, Cecener, Egeli, & Tunca, 2018; Guney Eskiler, Dikmen, & Genc, 2015; Güney, Genc, & Dikmen, 2011; Kapse‐Mistry, Govender, Srivastava, & Yergeri, 2014; Miao, Du, Yuan, Zhang, & Hu, 2013; Müller, Karsten, & Gohla, 2000).…”

Section: Introductionmentioning

confidence: 99%

Talazoparib nanoparticles for overcoming multidrug resistance in triple‐negative breast cancer

Eskiler

Çeçener

Egelí

et al. 2020

Journal Cellular Physiology

View full text Add to dashboard Cite

Herein, we investigated efflux pumps‐mediated talazoparib‐resistance in the treatment of triple‐negative breast cancer (TNBC). Furthermore, we produced a novel talazoparib‐solid lipid nanoparticles (SLNs) and then explored in vitro therapeutic efficacy of talazoparib‐SLNs to overcome talazoparib‐resistance in TNBC cells. Talazoparib‐SLNs formulation was produced and then characterized. Calcein and Rho‐123 were used to analyze the functional activity of drug efflux pumps in these cells. Additionally, RT‐PCR, western blot and immunofluorescence analysis were used to detect the messenger RNA, and protein expression level, and cellular localization of the multidrug resistance (MDR1), breast cancer resistance protein (BCRP), and MRP1. We found that talazoparib efflux was mediated by BCRP and MRP1 pumps in TNBC cells. Talazoparib‐SLNs could significantly enhance therapeutic efficacy of talazoparib. Furthermore, talazoparib‐SLNs were more effective in the suppression of MDR1, BCRP, and MRP1 gene and protein expression levels than talazoparib. Consequently, this study suggests that talazoparib‐SLNs formulation represents a promising therapeutic carrier to reverse MDR‐mediated resistance in TNBC.

show abstract

Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer

et al. 2018

View full text Add to dashboard Cite

Nano-based drug delivery system

Cited by 4 publications

References 136 publications

Magneto- and opto-stimuli responsive nanofibers as a controlled drug delivery system

Magneto- and opto-stimuli responsive nanofibers as a controlled drug delivery system

Talazoparib nanoparticles for overcoming multidrug resistance in triple‐negative breast cancer

Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer

Contact Info

Product

Resources

About